"Wait"??
O.K., makes sense for MLNM, but..... try this one.....
BTRN..... current market cap, $20.4 million. Cash in hand at end of last quarter, $20 million. Research premium relative to cash at end of last quarter....... approximately $0.4 million.
XenoMune..... controlling patents, IMO, for at least a portion of the art, including PERV. Substantial technical hurdles which, to my knowledge, may never be overcome. Project supported by Novartis, royalties to BTRN of about 5% (my estimate). Market approximately $4 billion??
AlloMune for graft-versus-lymphoma/leukemia..... we'll see.
AlloMune for solid organ transplantation...... not partnered, IND approved. Estimate of market is $1.4 billion, but may grow like a mushroom in peet, given success.
MEDI 507..... phase II for GvH, phase I for psoriasis. 10% "true" royalty from MEDI, minimum (but I assume maximum too.... that is, it is double digit, and that's all we know). Controlling patents with big-time life span. I estimate the MEDI indications (GvH and autoimmunity, with solid organ transplantation back-burnered) to be $3 billion.
So...... all of you gluttons..... Jeffrey?? David??....... that want to contribute to a valuation thread (yikes!)...... what's it worth? :-) |
